Success Metrics

Clinical Success Rate
100.0%

Based on 8 completed trials

Completion Rate
100%(8/8)
Active Trials
0(0%)
Results Posted
25%(2 trials)

Phase Distribution

Ph phase_1
2
25%
Ph phase_4
1
13%
Ph phase_3
3
38%
Ph phase_2
1
13%

Phase Distribution

2

Early Stage

1

Mid Stage

4

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
2(28.6%)
Phase 2Efficacy & side effects
1(14.3%)
Phase 3Large-scale testing
3(42.9%)
Phase 4Post-market surveillance
1(14.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

8 of 8 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

8

all time

Status Distribution
Completed(8)

Detailed Status

Completed8

Development Timeline

Analytics

Development Status

Total Trials
8
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (28.6%)
Phase 21 (14.3%)
Phase 33 (42.9%)
Phase 41 (14.3%)

Trials by Status

completed8100%

Recent Activity

0 active trials
Showing 5 of 8
completedphase_3

Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 2)

NCT04410991
completed

An Observational Study on Teriflunomide-exposed Pregnancies

NCT03198351
completedphase_4

To Evaluate the Safety and Efficacy of Teriflunomide in Patients With Relapsing Forms of Multiple Sclerosis

NCT03856619
completedphase_3

Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis

NCT00803049
completedphase_2

Long Term Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With Relapses

NCT00228163
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT04410991Phase 3

Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 2)

Completed
NCT03198351

An Observational Study on Teriflunomide-exposed Pregnancies

Completed
NCT03856619Phase 4

To Evaluate the Safety and Efficacy of Teriflunomide in Patients With Relapsing Forms of Multiple Sclerosis

Completed
NCT00803049Phase 3

Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis

Completed
NCT00228163Phase 2

Long Term Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With Relapses

Completed
NCT01863888Phase 3

Effect of Teriflunomide on Immune Cell Subsets in the Blood of Patients With Multiple Sclerosis

Completed
NCT02046629Phase 1

A Study to Evaluate the Pharmacokinetic Profiles of Single 14 mg Teriflunomide Tablet in Healthy Chinese Volunteers

Completed
NCT01239459Phase 1

Pharmacokinetic and Tolerability Study of 14 mg Single Dose of Teriflunomide in Subjects With Severe Renal Impairment

Completed

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8